These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35582586)

  • 21. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hrs interacts with sorting nexin 1 and regulates degradation of epidermal growth factor receptor.
    Chin LS; Raynor MC; Wei X; Chen HQ; Li L
    J Biol Chem; 2001 Mar; 276(10):7069-78. PubMed ID: 11110793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
    Thomas SM; Grandis JR; Wentzel AL; Gooding WE; Lui VW; Siegfried JM
    Neoplasia; 2005 Apr; 7(4):426-31. PubMed ID: 15967120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
    Jo U; Park KH; Whang YM; Sung JS; Won NH; Park JK; Kim YH
    Oncotarget; 2014 Mar; 5(5):1265-78. PubMed ID: 24658031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells
    Chiu HY; Chiang CM; Yeh SP; Jong DS; Wu LS; Liu HC; Chiu CH
    Oncol Lett; 2020 Nov; 20(5):206. PubMed ID: 32963612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells.
    Cruz Da Silva E; Choulier L; Thevenard-Devy J; Schneider C; Carl P; Rondé P; Dedieu S; Lehmann M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.
    Alfieri RR; Galetti M; Tramonti S; Andreoli R; Mozzoni P; Cavazzoni A; Bonelli M; Fumarola C; La Monica S; Galvani E; De Palma G; Mutti A; Mor M; Tiseo M; Mari E; Ardizzoni A; Petronini PG
    Mol Cancer; 2011 Nov; 10():143. PubMed ID: 22111840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocytosis and intracellular trafficking of ErbBs.
    Sorkin A; Goh LK
    Exp Cell Res; 2008 Oct; 314(17):3093-106. PubMed ID: 18793634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.
    Day TF; Kallakury BVS; Ross JS; Voronel O; Vaidya S; Sheehan CE; Kasid UN
    Mol Cancer Res; 2019 May; 17(5):1207-1219. PubMed ID: 30647104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking.
    Burke P; Schooler K; Wiley HS
    Mol Biol Cell; 2001 Jun; 12(6):1897-910. PubMed ID: 11408594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocytosis and intracellular trafficking of ErbBs.
    Sorkin A; Goh LK
    Exp Cell Res; 2009 Feb; 315(4):683-96. PubMed ID: 19278030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
    Wan Y; Yuan Y; Pan Y; Zhang Y
    Exp Ther Med; 2017 Jun; 13(6):3067-3074. PubMed ID: 28587381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
    Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
    Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.